HSP22 Antibody
Mouse Monoclonal 3C12-H11 IgG1 kappa
$50.00 to US & $70.00 to Canada for most products. Final costs are calculated at checkout.
Background
Hsp22 (HSPB8) is a 196-amino acid protein that is a member of the small heat shock protein super-family and the human protein is most closely related to Hsp27. Similar to most other sHSPs, Hsp22 is predominately transcribed in skeletal muscle and heart, as well as the placenta. Hsp22 is a monomeric protein which interacts with HSPB1. It displays temperature-dependent chaperone activity. In a two hybrid screen, HspB8 interacted preferentially with a triple aspartate form of Hsp27 which mimics Hsp27 phosphorylated at Ser15, Ser78, and Ser82, as compared to wild-type Hsp27. HSPB8 has two binding domains (N and C Terminal) that are specific for different binding partners, and has the ability to bind itself and other sHSPs (3). The chaperone-like activity is of great importance to the function of Hsp22 in various processes including proliferation, apoptosis and macroautophagy. Mutations in the HSPB8 gene are associated with the inherited peripheral neurpathies, autosomal dominant distal hereditary motor neuropathy type IIA (dSMA) and axonal Charcot-Marie-Tooth disease type 2L (CMT2L).
Product Details
Target Details
Application Details
Formulation
Shipping & Handling
This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.
